Response of recurrent high-grade glioma to treatment with 90Y-DOTATOC

Journal of Nuclear Medicine

Volumn 51, Issue 3, 2010, Pages 397-400

  Heute, Dirk ^a   Kostron, Herwig ^a   Von Guggenberg, Elisabeth ^a   Ingorokva, Shota ^a   Gabriel, Michael ^a   Dobrozemsky, Georg ^a   Stockhammer, Günther ^a   Virgolini, Irene J ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

90Y DOTATOC; Glioblastoma; Intracavitary treatment

Indexed keywords

[1,4,7,10 TETRAAZACYCLODODECANE N,N',N'',N'''NTETRAACETIC ACID 0 PHENYLALANINE 1 ,TYROSINE 3]OCTREOTIDE YTTRIUM Y 90; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 90Y OCTREOTIDE, DOTA TYR(3); 90Y-OCTREOTIDE, DOTA-TYR(3)-; DRUG DERIVATIVE; OCTREOTIDE;

ADULT; ARTICLE; CANCER GRADING; CASE REPORT; FEMALE; GLIOBLASTOMA; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; WORLD HEALTH ORGANIZATION; FEASIBILITY STUDY; GLIOMA; INJECTION; MIDDLE AGED; PATHOLOGY; RECURRENT DISEASE; SCINTISCANNING; TREATMENT OUTCOME; WHOLE BODY IMAGING;

FEASIBILITY STUDIES; FEMALE; GLIOMA; HUMANS; INJECTIONS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OCTREOTIDE; POSITRON-EMISSION TOMOGRAPHY; RECURRENCE; TREATMENT OUTCOME; WHOLE BODY IMAGING; YOUNG ADULT;

EID: 77950354746     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.072819     Document Type: Article

References (15)

1. Barnholtz-Sloan JS, Sloan AE, Schwartz AG. Relative survival rates and patterns of diagnosis analyzed by time period for individuals with primary malignant brain tumor, 1973-1997. J Neurosurg. 2003;99:458-466.
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-1006.
3. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003;5:79-88. (Pubitemid 36422560)
4. Virgolini I, Yang Q, Li S, et al. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors. Cancer Res. 1994;54:690-700. (Pubitemid 24068324)
5. Virgolini I, Raderer M, Kurtaran A, et al. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med. 1994;331:1116-1121. (Pubitemid 24321216)
6. 68Ga-DOTA TOC PET/CT. Eur J Nucl Med Mol Imaging. 2009;36:48-52.
7. Merlo A, Mueller-Brand J, Maecke HR. Comparing monoclonal antibodies and small peptidic hormones for local targeting of malignant gliomas. Acta Neurochir Suppl. 2003;88:83-91.
8. 90Y-DOTATOC) in neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2004;31:1038-1046.
9. Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med. 2002;32:148-155.
10. Beutler D, Avoledo P, Reubi JC, et al. Three-year recurrence-free survival in a patient with recurrent medulloblastoma after resection, high-dose chemotherapy, and intrathecal yttrium-90-labeled DOTA-Tyr3-octreotide radiopeptide brachytherapy. Cancer. 2005;103:869-873. (Pubitemid 40216418)
11. 90Y-labeled peptidic vector DOTA-TOC to control gliomas of WHO grades II and III: an extended pilot study. Eur J Nucl Med Mol Imaging. 2002;29:486-493.
12. 131I-TM-601. J Nucl Med. 2005;46:580-586.
13. 90Y-DOTATOC. J Nucl Med. 2006;47:105-112.
14. 18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma. Eur J Nucl Med Mol Imaging. 2006;33:792-800.
15. 3-octreotate in patients with endocrine gastroenteropancreatic tumours. J Clin Oncol. 2005;23:2754-2762.